|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating Activities: | |||||
| Net (loss) income | |||||
| Adjustments to reconcile net (loss) income to net cash provided by operating activities: | |||||
| Share-based compensation | |||||
| Depreciation | |||||
| Amortization of debt issuance costs | |||||
| Amortization | |||||
| Amortization of operating lease assets | |||||
| Remeasurement of contingent consideration to fair value | |||||
| Remeasurement of derivative instruments, net | |||||
| Gain on sale of asset | |||||
| Loss (gain) on investment revaluation - Ceribell, Inc. | |||||
| Loss on debt extinguishment | |||||
| Impairment of disposal group and loss on sale | |||||
| Deferred income tax expense (benefit) | |||||
| Impairment of investments | |||||
| Impairment of long-lived assets | |||||
| ACS inventory obsolescence adjustment | |||||
| Other | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable, net | |||||
| Inventories | |||||
| Other current and non-current assets | |||||
| Accounts payable and accrued current and non-current liabilities | |||||
| Taxes payable | |||||
| SNIA environmental liability | |||||
| Litigation provision liability | |||||
| Net cash provided by operating activities | |||||
| Investing Activities: | |||||
| Purchases of property, plant, and equipment | |||||
| Proceeds from sale of investment | |||||
| Proceeds from asset sales | |||||
| Purchases of investments | |||||
| Acquisitions, net of cash acquired | |||||
| Proceeds from sale of Heart Valves, net of cash disposed | |||||
| Proceeds from sale of Respicardia investment and loan | |||||
| Net cash used in investing activities | |||||
| Financing Activities: | |||||
| Repayment of long-term debt obligations | |||||
| Shares repurchased from employees for minimum tax withholding | |||||
| Repayments of short-term borrowings (maturities greater than 90 days) | |||||
| Proceeds from exercise of stock options | |||||
| Proceeds from long-term debt obligations | |||||
| Payment of debt extinguishment costs | |||||
| Purchase of capped calls | |||||
| Proceeds from unwind of capped calls | |||||
| Payment of contingent consideration | |||||
| Payment of debt issuance costs | |||||
| Payment of make-whole premium on long-term debt obligations | |||||
| Proceeds from deferred consideration from sale of Heart Valves, net of working capital adjustments | |||||
| Other | |||||
| Net cash (used in) provided by financing activities | |||||
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | |||||
| Net (decrease) increase in cash, cash equivalents, and restricted cash | |||||
| Cash, cash equivalents, and restricted cash at beginning of period | |||||
| Cash, cash equivalents, and restricted cash at end of period | |||||
| Cash paid for interest | |||||
| Cash paid (received) for income taxes, net | |||||
Loading...